Weight Loss
Top in cardiology: COVID-19 linked to increased CV risk; semaglutide improves HF symptoms
Researchers found that patients with a positive SARS-CoV-2 PCR test faced an increased risk for major adverse cardiac events vs. individuals without SARS-CoV-2; this risk was even higher among patients hospitalized for COVID-19.
Wegovy improves exercise function in obesity-related HF with concomitant weight loss
Semaglutide 2.4 mg was linked to early, sustained improvement in exercise function among patients with obesity-related HF and improved most among those with the largest proportionate weight loss, a speaker reported.
VIDEO: Important to carefully weigh benefits, risks of different diabetes medications
In this video, David Nathan, MD, discusses the side effects of weight loss caused by type 2 diabetes medications and the risks of prescribing these medications to patients without diabetes.
Dietetic intervention trial in ILD feasible, helps stop weight loss
A 12-week dietetic intervention trial in patients with interstitial lung disease and malnutrition was feasible and helped patients stop losing weight, according to a poster at the European Respiratory Society International Congress.
Osteoarthritis recommendations lack ‘granular guidance’ on exercise, weight loss
SAN DIEGO — Although most osteoarthritis experts agree that diet and exercise are critical to disease management, detailed guidance on either remain lacking, according to a presenter at the 2024 Congress of Clinical Rheumatology West.
Novel obesity agent linked to weight loss vs. placebo at 3 months in patients with HFpEF
In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.
Positive trial of ponsegromab may signal ‘start of a revolution’ for cancer cachexia
A randomized phase 2 trial of individuals with cancer cachexia showed those assigned ponsegromab gained significantly more weight than those assigned placebo.
‘It’s going to be ubiquitous’: Weight loss drugs may aid rheumatic disease treatment
SAN DIEGO — GLP-1 agonists and other drugs that have recently made headlines for their weight loss applications will be useful in helping patients meet goals in psoriatic arthritis and other rheumatic diseases, according to a speaker here.
One in four adults would use a weight loss drug without consulting a physician
A quarter of adults would consider using an injectable weight loss drug without consulting a health care provider, according to the results of a survey from The Ohio State University Wexner Medical Center.
Top in endocrinology: Coffee, tea reduce cardiometabolic risk; novel weight loss drug
Drinking caffeinated beverages as an adult may lower the risk for developing multiple cardiometabolic diseases compared with adults who do not consume caffeine, according to study findings.